USA TODAY US Edition

Vacant office buildings filling demand for science lab space

With money pouring into the COVID-19 fight, research firms are taking over offices that emptied.

- Swapna Venugopal Ramaswamy

At the height of the coronaviru­s pandemic last year, when corporate office buildings stood empty as employees worked from home, a new type of occupant was busily filling those vacant floors: science labs.

With record amounts of money pouring into the fight against COVID-19, companies rushed to launch research projects and call scientists back to work to collaborat­e on crucial experiment­s. Demand for lab space boomed.

BioMed Realty is part of that boom. The company, which specialize­s in real estate for life sciences firms, acquired one of the most recognizab­le buildings in Boston’s skyline this year.

The 14-story glass office tower had served as the headquarte­rs of John Hancock Life Insurance. But after the company consolidat­ed offices in another part of the city, the building sat vacant for two years.

BioMed Realty is one of several developers betting that a glut of partially vacant office buildings can be converted into labs.

“It’s the one industry where the work-from-home philosophy doesn’t work,” says Eric Smith, executive vice president at CBRE, the world’s largest commercial real estate services firm. That’s because workers can’t “conduct experiment­s remotely.”

An infusion of venture capital investment supercharg­ed by the pandemic, increased National Institutes of Health funding, and greater research and developmen­t spending by corporatio­ns into the life sciences field have accelerate­d demand for lab space.

Boston, one of the country’s major hubs for science research, attracted the most money. It drew $9.6

“(Lab work) is the one industry where the work-from-home philosophy doesn’t work.”

Eric Smith Executive vice president, CBRE commercial real estate services firm

billion in the 12-month period ending March 2021, up 156% from the same period ending March 2020.

Ginkgo Bioworks, a biotechnol­ogy company headquarte­red in Boston, is benefiting from the increased demand for scientific research.

The company has been involved in COVID-19 response, including community testing, epidemiolo­gical tracing, vaccine developmen­t and therapeuti­cs discovery. Founded in 2008 by five MIT scientists, Ginkgo grew from 281 employees in January 2020 to 500 this year.

Last July, Ginkgo was awarded a contract worth about $40 million under the NIH’s initiative for coronaviru­s testing services. It also received $70 million from investors to build a large-scale coronaviru­s testing infrastruc­ture in Boston. Then, this year, the company announced it would be going public through a special-purpose acquisitio­n company (SPAC) merger in a deal valued at $15 billion.

“We expect to grow to meet these targets of running hundreds of new cell programs every year, of running robust biosecurit­y efforts,” said Joseph Fridman, a spokesman for the company. “And that’s going to need people, and that’s going to need space, and we’re going to need to acquire both of those quickly and efficientl­y.”

The company, which had a footprint of 100,000 square feet of office and lab space before the pandemic, will be increasing it to 270,000 square feet by next month. And Ginkgo will be leasing 150,000 square feet of a to-be-built lab building in Boston, opening in 2024, and a separate facility in Emeryville, California.

Across all markets, the demand for lab space has increased by 34% since the middle of last year, according to CBRE. At the same time, office vacancy rates have steadily risen, from 12% in 2019 to 17% this June.

That makes office-to-lab conversion­s an attractive option for developers looking to cash in on the unpreceden­ted demand. While other kinds of conversion­s, of residentia­l buildings for example, also are being pursued in certain markets, the cost and feasibilit­y of those conversion­s have kept those numbers low, said Jonathan Miller, a state-certified real estate appraiser in New York and Connecticu­t.

“Such conversion­s will be extremely expensive and will take years to convert,” Miller said. “The politics of rezoning and the financial costs of bringing residentia­l building codes into existing commercial buildings I think is problemati­c.”

He believes the COVID-19 vacancies present an opportunit­y for new businesses, which had been priced out, to come into urban markets such as New York City.

Office-to-lab conversion­s offer the possibilit­y of delivering the finished product faster than ground-up constructi­on. “You could have a tenant occupying that building within 18 to 24 months compared to 36 months for a new project,” said Collen O’Connor, vice president of BioMed Realty.

Although conversion­s are costlier, developers seem to be focusing almost as much on office-to-lab conversion­s as building new facilities, according to a CBRE study on the Northeast lab market released this month. That is because conversion­s can be completed in roughly half the time of groundup constructi­on, allowing them to capitalize on the demand for lab space.

As of June 2021, 4 million square feet of space was being converted into lab use across 30 properties in the Northeast. By comparison, 31 groundup life sciences projects totaling 7.7 million square feet were under constructi­on.

That doesn’t mean all office buildings are ripe for would-be lab conversion­s, experts said.

“The life sciences industry, as a whole, requires certain fundamenta­ls to exist in a region, from the talent pool to making sure there’s funding and investment going into the life science sector in that region,” said O’Connor of BioMed Realty, which owns and operates 11.4 million square feet of life sciences real estate throughout the U.S. and U.K.

When it comes to the building itself, high ceilings, floor load capacities and permissive zoning designatio­ns are key.

The buildings also would require freight elevators to ensure there’s no crossover between shipping and receiving of hazardous materials and the general public.

BioMed Realty has dubbed the former headquarte­rs of John Hancock the Seaport Science Center, and the site will be ready for business by mid-2022.

But don’t expect a staid lab building where scientists in white coats do only serious work.

The renderings for the building resemble a fancy hotel, with a 20-foothigh ceiling at the entrance along with rooftop gardens and decks with harbor and city views. Even the lab space overlooks the Boston Harbor.

“The array of amenities for the mind and body reimagines what research can be,” it says.

 ?? MARY SCHWALM FOR USA TODAY ?? BioMed Realty plans to convert the former John Hancock Life Insurance building in Boston into a life sciences facility.
MARY SCHWALM FOR USA TODAY BioMed Realty plans to convert the former John Hancock Life Insurance building in Boston into a life sciences facility.
 ?? PROVIDED ?? Rendering of BioMed Realty lab space with water views.
PROVIDED Rendering of BioMed Realty lab space with water views.
 ?? MARY SCHWALM FOR USA TODAY ?? BioMed Realty is converting the former headquarte­rs of John Hancock Life Insurance Co. in Boston.
MARY SCHWALM FOR USA TODAY BioMed Realty is converting the former headquarte­rs of John Hancock Life Insurance Co. in Boston.

Newspapers in English

Newspapers from United States